These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35706734)

  • 1. Solriamfetol for the Use of Narcolepsy: A Systematic Review.
    Iturburu A; Pallares Vela E; Cruz C; Yepez M; Ortiz JF; Krishna K; Peña G; Cordova S; Khurana M; Bandarupalli P
    Cureus; 2022 May; 14(5):e24937. PubMed ID: 35706734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial.
    Dauvilliers Y; Shapiro C; Mayer G; Lammers GJ; Emsellem H; Plazzi G; Chen D; Carter LP; Lee L; Black J; Thorpy MJ
    CNS Drugs; 2020 Jul; 34(7):773-784. PubMed ID: 32588401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological Interventions for Excessive Daytime Sleepiness in Adults with Narcolepsy: A Systematic Review and Network Meta-Analysis.
    Chien PY; Kuo CY; Lin MH; Chang YJ; Hung CC
    J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of solriamfetol for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: a systematic review and meta-analysis of clinical trials.
    Subedi R; Singh R; Thakur RK; K C B; Jha D; Ray BK
    Sleep Med; 2020 Nov; 75():510-521. PubMed ID: 33032062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient Selection and Perspectives.
    Abad VC
    Nat Sci Sleep; 2021; 13():75-91. PubMed ID: 33531850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solriamfetol: A Review in Excessive Daytime Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnoea.
    Hoy SM
    CNS Drugs; 2023 Nov; 37(11):1009-1020. PubMed ID: 37847434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advances in treatment of narcolepsy].
    Xu Q; Lou G; Wang T; Zhang L
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2020 Aug; 49(4):419-424. PubMed ID: 32985153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recently Approved and Upcoming Treatments for Narcolepsy.
    Thorpy MJ
    CNS Drugs; 2020 Jan; 34(1):9-27. PubMed ID: 31953791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solriamfetol Titration & AdministRaTion (START) in Patients With Narcolepsy.
    Thorpy MJ; Hyman D; Parks GS; Chen A; Foley C; Baldys B; Ito D; Singh H
    Clin Ther; 2022 Oct; 44(10):1356-1369. PubMed ID: 36171171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solriamfetol for the Management of Excessive Daytime Sleepiness.
    Cuomo MC; Sheehan AH; Jordan JK
    J Pharm Pract; 2022 Dec; 35(6):963-970. PubMed ID: 33882756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications.
    Thorpy MJ; Bogan RK
    Sleep Med; 2020 Apr; 68():97-109. PubMed ID: 32032921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials.
    Meskill GJ; Davis CW; Zarycranski D; Doliba M; Schwartz JC; Dayno JM
    CNS Drugs; 2022 Jan; 36(1):61-69. PubMed ID: 34935103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Living with Narcolepsy: Current Management Strategies, Future Prospects, and Overlooked Real-Life Concerns.
    Barker EC; Flygare J; Paruthi S; Sharkey KM
    Nat Sci Sleep; 2020; 12():453-466. PubMed ID: 32765142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solriamfetol real world experience study (SURWEY): Initiation, titration, safety, effectiveness, and experience during follow-up for patients with narcolepsy from Germany.
    Winter Y; Mayer G; Kotterba S; Benes H; Burghaus L; Koch A; Girfoglio D; Setanoians M; Kallweit U
    Sleep Med; 2023 Mar; 103():138-143. PubMed ID: 36796288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. pitolisant, a novel histamine-3 receptor competitive antagonist, and inverse agonist, in the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
    Sarfraz N; Okuampa D; Hansen H; Alvarez M; Cornett EM; Kakazu J; Kaye AM; Kaye AD
    Health Psychol Res; 2022; 10(3):34222. PubMed ID: 35774905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea.
    Malhotra A; Shapiro C; Pepin JL; Hedner J; Ahmed M; Foldvary-Schaefer N; Strollo PJ; Mayer G; Sarmiento K; Baladi M; Chandler P; Lee L; Schwab R
    Sleep; 2020 Feb; 43(2):. PubMed ID: 31691827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to Onset of Response to Pitolisant for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients With Narcolepsy: An Analysis of Randomized, Placebo-Controlled Trials.
    Watson NF; Davis CW; Zarycranski D; Vaughn B; Dayno JM; Dauvilliers Y; Schwartz JC
    CNS Drugs; 2021 Dec; 35(12):1303-1315. PubMed ID: 34822113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy.
    Szabo ST; Thorpy MJ; Mayer G; Peever JH; Kilduff TS
    Sleep Med Rev; 2019 Feb; 43():23-36. PubMed ID: 30503715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression.
    Krystal AD; Benca RM; Rosenberg R; Schweitzer PK; Malhotra A; Babson K; Lee L; Bujanover S; Strohl KP
    J Psychiatr Res; 2022 Nov; 155():202-210. PubMed ID: 36070638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy.
    Rosenberg R; Thorpy MJ; Dauvilliers Y; Schweitzer PK; Zammit G; Gotfried M; Bujanover S; Scheckner B; Malhotra A
    J Clin Sleep Med; 2022 Jan; 18(1):235-244. PubMed ID: 34283019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.